Owkin Breast Cancer AI LoopAccess high-quality research-grade patient data and cutting-edge clinical expertise
Breast cancer remains the most common cancer in women, worldwide. More than two million are diagnosed each year and 15% of early-stage breast cancer patients will relapse. This is why we created a Federated Research Ecosystem bringing academic and pharmaceutical industry researchers together to advance medical research and accelerate drug development.
- Distributed Data Access: Through Owkin Connect, our federated learning platform, we can train machine learning models on distributed data without moving it from behind the hospital firewalls. In the Healthchain project, we investigate the response to neoadjuvant chemotherapy in breast cancer patients, using Institut Curie and Centre Léon Bérard’s digital pathology datasets.
- Augmented Research Teams: Renowned academic institutions such as Gustave Roussy Institute, recently ranked 5th World Best Cancer Hospital, use our collaborative software tool, Owkin Studio, and our expertise in data science to predict relapse for Breast Cancer patients in the Race-AI project.
- Novel Research Solutions: Integrate our breast AI models in translational & clinical research workflows. They can be implemented to improve understanding of outcomes & response to treatment, develop clinical applications that help you identify & stratify patients in clinical trials, and more.
How AI models & federated learning can predict breast cancer outcomes? Our experts Fabrice André and Magali Lacroix-Triki from Gustave Roussy Institute, Pierre Heudel from Léon Bérard Center, Guillaume Bataillon from Curie Institute presented their research with data scientists from Owkin during a 1-hour webinar. Register here to watch it on-demand!
“We started working with Owkin in 2019 to predict breast cancer recurrence and it’s been a very enriching experience. They bring AI expertise and tools to make our projects reach the highest levels. I trust them to handle data with care, with high-security standards, and to work with them on putting this into industrialization.”– Magali Lacroix-Triki, Pathologist at Gustave Roussy Institute
“It’s thrilling to start such a project with Owkin and Institut Curie. Federated Learning is a pioneering technology, and we hope that this project will help show the impact it can have.”Pierre-Etienne Heudel, oncologist at the Léon Bérard Center